Literature DB >> 12377975

Hypersensitivity pneumonitis related to imatinib mesylate.

A Bergeron, E Bergot, G Vilela, L Ades, A Devergie, H Espérou, G Socié, F Calvo, E Gluckman, P Ribaud, Ph Rousselot, A Tazi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12377975     DOI： 10.1200/JCO.2002.99.179

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

1.  A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months.

Authors:  Koichiro Suemori; Hiroshi Fujiwara; Seiichiro Watanabe; Taichi Azuma; Masaki Yasukawa
Journal:  Int J Hematol       Date:  2010-11-26       Impact factor: 2.490

Review 2.  Diagnostic strategy in cancer patients with acute respiratory failure.

Authors:  Elie Azoulay; Benoît Schlemmer
Journal:  Intensive Care Med       Date:  2006-04-29       Impact factor: 17.440

3.  Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.

Authors:  Dongho Kim; Hyun-Gyung Goh; Soo-Hyun Kim; Byung-Sik Cho; Dong-Wook Kim
Journal:  Int J Hematol       Date:  2011-09-08       Impact factor: 2.490

Review 4.  Interstitial lung disease in lung cancer: separating disease progression from treatment effects.

Authors:  Sarah Danson; Fiona Blackhall; Paul Hulse; Malcolm Ranson
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 5.  Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies.

Authors:  Bobbak Vahid; Paul E Marik
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

6.  Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data.

Authors:  Kim Dao; Dana Védy; José Lopez; Olivier Staneczek; Thierry Buclin; Françoise Livio
Journal:  Int J Hematol       Date:  2012-12-28       Impact factor: 2.490

Review 7.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors:  J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal:  Leukemia       Date:  2016-04-28       Impact factor: 11.528

8.  Nilotinib-induced interstitial lung disease.

Authors:  Se-Il Go; Won Sup Lee; Gyeong-Won Lee; Jung Hun Kang; Myung Hee Kang; Jeong-Hee Lee; Hoon-Gu Kim
Journal:  Int J Hematol       Date:  2013-07-23       Impact factor: 2.490

9.  Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Authors:  Martin Henkes; Heiko van der Kuip; Walter E Aulitzky
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.